Barclays PLC Global Blood Therapeutics, Inc. Call Options Transaction History

Barclays PLC

9 transactions

Quarter	Operation	Price Per call	calls change	calls Held
Q4 2019 Feb 10, 2020	BUY	$45.7 - $81.86 $2.29 Million - $4.09 Million	50,000 Added 5000.0%	51,000 $4.05 Million
Q3 2019 Nov 14, 2019	SELL	$45.35 - $57.91 $1.56 Million - $1.99 Million	-34,300 Reduced 97.17%	1,000 $49,000
Q2 2019 Aug 14, 2019	BUY	$52.6 - $63.29 $1.79 Million - $2.16 Million	34,100 Added 2841.67%	35,300 $1.86 Million
Q1 2019 May 15, 2019	SELL	$39.99 - $53.48 $2.09 Million - $2.8 Million	-52,300 Reduced 97.76%	1,200 $64,000
Q4 2018 Feb 14, 2019	BUY	$31.54 - $46.67 $1.45 Million - $2.14 Million	45,900 Added 603.95%	53,500 $2.2 Million
Q3 2018 Nov 14, 2018	SELL	$38.0 - $51.1 $1.32 Million - $1.77 Million	-34,700 Reduced 82.03%	7,600 $289,000
Q2 2018 Aug 14, 2018	BUY	$38.7 - $50.15 $1.58 Million - $2.05 Million	40,800 Added 2720.0%	42,300 $1.91 Million
Q1 2018 May 15, 2018	SELL	$39.6 - $65.9 $1.02 Million - $1.69 Million	-25,700 Reduced 94.49%	1,500 $72,000
Q4 2017 Feb 14, 2018	BUY	$29.7 - $45.7 $807,840 - $1.24 Million	27,200	27,200 $1.07 Million

288K

Ticker GBT
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 67,476,200
Market Cap $4.62B
Description
Global Blood Therapeutics, Inc., a biopharmaceutical company, engages in the discovery, development, and delivery of treatments for underserved patient communities with sickle cell disease (SCD). The company offers Oxbryta tablets, an oral, once-daily therapy for SCD. It also evaluates the safety and pharmacokinetics of single and multiple doses...

Get notified when there are updates to the investment portfolio of Barclays PLC, based on Form 13F filings with the SEC.

Stay updated on Barclays PLC with notifications on news.